Co-administration of vaccines: a focus on tetravalent Measles-Mumps-Rubella-Varicella (MMRV) and meningococcal C conjugate vaccines

References

• Vesikari T, Karvonen A, Bianco V, Van der Wielen M, Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles–mumps–rubella–varicella vaccine during the second year of life: an open, randomized controlled trial. Vaccine. 2011;29(25):4274–84. doi:10.1016/j.vaccine.2011.03.043.
   PubMed Web of Science ®Google Scholar
• Klein NP, Shepard J, Bedell L, Odrljin T, Dull P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine. 2012;30(26):3929–36. doi:10.1016/j.vaccine.2012.03.080.
   PubMed Web of Science ®Google Scholar
• Masters NB, Wagner AL, Carlson BF, Boulton ML. Vaccination timeliness and co-administration among Kenyan children. Vaccine. 2018;36(11):1353–60. doi:10.1016/j.vaccine.2018.02.001.
   PubMed Web of Science ®Google Scholar
• Giammanco G, Moiraghi A, Zotti C, Pignato S, Li Volti S, Giammanco A, Soncini R. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules. Multicenter working group. Vaccine. 1998;16(7):722–26. doi:10.1016/s0264-410x(97)00250-8.
   PubMed Web of Science ®Google Scholar
• Durando P, Esposito S, Bona G, Cuccia M, Desole MG, Ferrera G, Gabutti G, Pellegrino A, Salvini F, Henry O, et al. The immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children: A phase IIIb, randomized, multi-center study in Italy. Vaccine. 2016;34(36):4278–84. doi:10.1016/j.vaccine.2016.07.009.
   PubMed Web of Science ®Google Scholar
• Findlow H, Borrow R. Interactions of conjugate vaccines and co-administered vaccines. Hum Vaccin Immunother. 2016;12(1):226–30. doi:10.1080/21645515.2015.1091908.
   PubMed Web of Science ®Google Scholar
• Eskola J, Ölander R-M, Hovi T, Litmanen L, Peltola S, Käyhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet. 1996;348(9043):1688–92. doi:10.1016/S0140-6736(96)04356-5.
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO). Expert committee on biological standardization. Recommendations to assure the quality, safety and efficacy of DT-based combined vaccines; Technical Report Series No. 980, Annex 6; 2014. [accessed 2019 Sep 4]. https://www.who.int/biologicals/WHO_TRS_980_WEB.pdf.
   Google Scholar
• Kroger AT, Duchin J, Vázquez M General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). [ accessed 2019 Sep. 4]. www.cdc.gov/vaccines/recs/storage/toolkit/default.html.
   Google Scholar
• Center for Disease Control and Prevention (CDC). Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination Measles, Mumps, Rubella, and Varicella Vaccine. [accessed 2019 Sept]. https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5903a1.htm.
   Google Scholar
• Anh DD, Van Der Meeren O, Karkada N, Assudani D, Yu T-W, Han HH. Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus- Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: an open-label, phase III study. Hum Vaccin Immunother. 2016;12(3):655–57. doi:10.1080/21645515.2015.1084451.
   PubMed Web of Science ®Google Scholar
• Halsey NA. Combination vaccines: defining and addressing current safety concerns. Clin Infect Dis. 2001;33(Suppl 4):S312–8. doi:10.1086/322567.
   PubMedGoogle Scholar
• Skibinski D, Baudner B, Singh M, O′Hagan DT. Combination vaccines. J Glob Infect Dis. 2011;3(1):63. doi:10.4103/0974-777X.77298.
   PubMedGoogle Scholar
• World Health Organization (WHO). Vaccine safety basics combination vaccines. [ accessed 2019 Sep 4]. https://vaccine-safety-training.org/combination-vaccines.html.
   Google Scholar
• Giammanco G, Li Volti S, Mauro L, Bilancia GG, Salemi I, Barone P, Musumeci S. Immune response to simultaneous administration of a recombinant DNA hepatitis B vaccine and multiple compulsory vaccines in infancy. Vaccine. 1991;9(10):747–50. doi:10.1016/0264-410x(91)90291-d.
   PubMed Web of Science ®Google Scholar
• Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine. 2010;28(18):3171–79. doi:10.1016/j.vaccine.2010.02.045.
   PubMed Web of Science ®Google Scholar
• Klein NP, Abu-Elyazeed R, Baine Y, Cheuvart B, Silerova M, Mesaros N. Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants. Hum Vaccin Immunother. 2019;15(2):327–38. doi:10.1080/21645515.2018.1526586.
   PubMed Web of Science ®Google Scholar
• Nakashima K, Aoshima M, Ohfuji S, Yamawaki S, Nemoto M, Hasegawa S, Noma S, Misawa M, Hosokawa N, Yaegashi M, et al. Immunogenicity of simultaneous versus sequential administration of a 23-valent pneumococcal polysaccharide vaccine and a quadrivalent influenza vaccine in older individuals: A randomized, open-label, non-inferiority trial. Hum Vaccin Immunother. 2018;14(8):1923–30. doi:10.1080/21645515.2018.1455476.
   PubMed Web of Science ®Google Scholar
• Thompson AR, Klein NP, Downey HJ, Patterson S, Sundaraiyer V, Watson W, Clarke K, Jansen K, Sebastian S, Gruber WC, et al. Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial. Hum Vaccin Immunother. 2019;15(2):444–51. doi:10.1080/21645515.2018.1533777.
   PubMed Web of Science ®Google Scholar
• Macias Parra M, Gentile A, Vazquez Narvaez JA, Capdevila A, Minguez A, Carrascal M, Willemsen A, Bhusal C, Toneatto D. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial. Vaccine. 2018;36(50):7609–17. doi:10.1016/j.vaccine.2018.10.096.
   PubMed Web of Science ®Google Scholar
• Dbaibo G, Tinoco Favila JC, Traskine M, Jastorff A. Van der Wielen M. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study. Vaccine. 2018;36(28):4102–11. doi:10.1016/j.vaccine.2018.05.046.
   PubMed Web of Science ®Google Scholar
• Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P. Safety and immunogenicity of a novel quadrivalent Meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J. 2012;31(1):64–71. doi:10.1097/INF.0b013e31823dce5c.
   PubMed Web of Science ®Google Scholar
• Nolan TM, Nissen MD, Naz A, Shepard J, Bedell L, Hohenboken M, Odrljin T, Dull PM. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. Hum Vaccin Immunother. 2014;10(2):280–89. doi:10.4161/hv.27051.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Tregnaghi M, Keshavan P, Ypma E, Han L, Smolenov I. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after co-administration. Pediatr Infect Dis J. 2015;35(1):1. doi:10.1097/INF.0000000000000930.
   Web of Science ®Google Scholar
• Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26(6):496–500. doi:10.1097/INF.0b013e31805d7f17.
   PubMed Web of Science ®Google Scholar
• Alberer M, Burchard G, Jelinek T, Reisinger E, Beran J, Meyer S, Forleo-Neto E, Gniel D, Dagnew AF, Arora AK. Co-administration of a meningococcal glycoconjugate ACWY vaccine with travel vaccines: A randomized, open-label, multi-center study. Travel Med Infect Dis. 2014;12(5):485–93. doi:10.1016/j.tmaid.2014.04.011.
   PubMed Web of Science ®Google Scholar
• Koslap-Petraco MB, Judelsohn RG. Societal impact of combination vaccines: experiences of physicians, nurses, and parents. J Pediatr Heal Care. 2008;22(5):300–09. doi:10.1016/j.pedhc.2007.09.004.
   PubMed Web of Science ®Google Scholar
• Fendrick AM, Lee JH, LaBarge C, Glick HA. Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: estimating cost-effectiveness using decision analysis. Arch Pediatr Adolesc Med. 1999;153(2):126–36. [accessed 2019 Sep 4]. http://www.ncbi.nlm.nih.gov/pubmed/9988242.
   PubMedGoogle Scholar
• Zhou F, Santoli J, Messonnier ML, Yusuf HR, Shefer A, Chu SY, Rodewald L, Harpaz R. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med. 2005;159(12):1136. doi:10.1001/archpedi.159.12.1136.
   PubMedGoogle Scholar
• Zhou F, Shefer A, Wenger J, Messonnier M, Wang LY, Lopez A, Moore M, Murphy TV, Cortese M, Rodewald L. Economic evaluation of the routine childhood immunization program in the United States, 2009. Pediatrics. 2014;133(4):577–85. doi:10.1542/peds.2013-0698.
   PubMed Web of Science ®Google Scholar
• Macartney K, Gidding HF, Trinh L, Wang H, Dey A, Hull B, Orr K, McRae J, Richmond P, Gold M, et al. Evaluation of combination Measles-Mumps-Rubella-Varicella Vaccine introduction in Australia. JAMA Pediatr. 2017;171(10):992. doi:10.1001/jamapediatrics.2017.1965.
   PubMed Web of Science ®Google Scholar
• Summary of Product Characteristics Advisory Group. An agency of European Union – guideline of summary of product characteristics - European medicines agency- science medicines health. [ accessed 2019 Sep 4]. https://ec.europa.eu/health//sites/health/files/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf.
   Google Scholar
• President of the Italian Republic. Legislative Decree April 24, 2006, n° 219 Implementation of EU Directive 2001/83/EC (and subsequent amending directives) relative to a community code concerning medicinal products for human use, as well as of EU Directive 2003/94/EC. [ accessed 2019 Sep 4]. https://www.gazzettaufficiale.it/eli/id/2006/06/21/006G0237/sg.
   Google Scholar
• Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):e44–e100. doi:10.1093/cid/cit684.
   PubMed Web of Science ®Google Scholar
• Neels P, Southern J, Abramson J, Duclos P, Hombach J, Marti M, Fitzgerald-Husek A, Fournier-Caruana J, Hanquet G. Off-label use of vaccines. Vaccine. 2017;35(18):2329–37. doi:10.1016/j.vaccine.2017.02.056.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. General recommendations on immunization. Simultaneus and Non simultaneus Administration. [ accessed 2019 September 4]. https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html.
   Google Scholar
• O’Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2014;74(1):15–30. doi:10.1007/s40265-013-0155-7.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease Prevention and Control (ECDC). Immunisation and vaccines -Vaccination schedules for individual European countries and specific age groups. [ accessed 2019 Sep 4]. https://vaccine-schedule.ecdc.europa.eu/.
   Google Scholar
• GOV.UK Public Health England. The complete routine immunisation schedule from autumn 2018 Ref: PHE gateway number 2018450. [ accessed 2019 Sep 4]. https://www.gov.uk/government/collections/immunisation.
   Google Scholar
• Ministry of Health. National Vaccine Prevention Plan (PNPV) 2017-2019. [ accessed 2019 Sep 4]. https://www.gazzettaufficiale.it/eli/id/2017/02/18/17A01195/sg.
   Google Scholar
• European Commission Directorate. Off-label use of medicinal products. [ accessed 2019 Sep 5]. http://ec.europa.eu/health/sites/health/files/files/documents/2017_02_28_final_study_report_on_off-.
   Google Scholar
• “Off-Label” and Investigational Use Of Marketed Drugs. Biologics, and medical devices. [ accessed 2019 Sep 5]. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/label-and-investigational-use-marketed-drugs-biologics-and-medical-devices.
   Google Scholar
• Committee On Drugs. Off-Label use of drugs in children. Pediatrics. 2014;110(1 pt 1):181–83. doi:10.1542/peds.110.1.181.
   Google Scholar
• Revelle P. Use of MedDRA: focus on the new scope of adverse scope of adverse event reporting. MSSO Presentations 2012. Conference/meeting 29 November 2012, Silver Spring, MD. [ accessed Sep 5, 2019]. https://www.meddra.org/sites/default/files/page/documents_insert/revelle_icsr_info_day_nov_2012_final.pdf.
   Google Scholar
• Canadian Agency for Drugs and Technologies in Health (CADTH) Tools. Off-Label use of drugs. Questions and answers about the off-label use of drugs for health care providers. What does off-label mean?. [ accessed 2019 Sep 5]. https://www.canada.ca/en/health-.
   Google Scholar
• Tseng HF, Sy LS, Qian L, Marcy SM, Jackson LA, Glanz J, Nordin J, Baxter R, Naleway A, Donahue J, et al. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis. 2013;56(3):315–21. doi:10.1093/cid/cis871.
   PubMed Web of Science ®Google Scholar
• McGrath LJ, Brookhart MA. On-label and off-label use of high-dose influenza vaccine in the United States, 2010–2012. Hum Vaccin Immunother. 2015;11(3):537–44. doi:10.1080/21645515.2015.1011026.
   PubMed Web of Science ®Google Scholar
• Daskalaki I, Spain CV, Long SS, Watson B. Implementation of rotavirus immunization in Philadelphia, Pennsylvania: high levels of vaccine ineligibility and off-label use. Pediatrics. 2008;122(1):e33–e38. doi:10.1542/peds.2007-2464.
   PubMed Web of Science ®Google Scholar
• L’Ecluse P, Longeval C, T’Syen K, Bael, Bellis V. Off-label use of medicinal products and product liability. https://content.next.westlaw.com/8-525-5657?transitionType=Default&contextData=(sc.Default)&__lrTS=20190402003211431&firstPage=true&bhcp=1.
   Google Scholar
• President of the Italian Republic. Legislative Decree, February 17,1998, N. 23, converted, with amendments, in Law, Apri 8, 1998, No. 94 paragraph 2, article 3, so-called “Di Bella Law”. [ accessed 2019 Sep 4]. https://www.gazzettaufficiale.it/eli/id/1998/05/08/098A3335/sg.
   Google Scholar
• President of the Italian Republic. LAW March 8, 2017, No. 24 Provisions on the safety of care and the person assisted, as well as on the professional responsibility of the operators of the health professions. Official Journal of Italian Republic. [ accessed 2019 Sep 4]. https://www.gazzettaufficiale.it/eli/id/2017/03/17/17G00041/sg.
   Google Scholar
• European Agency of Medicines. ProQuad: EPAR-product information. [ accessed 2019 Sep 4]. https://www.ema.europa.eu/en/documents/product-information/proquad-epar-product-information_en.pdf.
   Google Scholar
• Agenzia Italiana del Farmaco. Priorix Tetra. Summary of product characteristics [Italian]. [ accessed 2019 Sep 4]. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000200_038200_RCP.pdf&retry=0&sys=m0b1l3.
   Google Scholar
• Scott LJ. Measles–mumps–rubella–varicella combination vaccine (ProQuad®): a guide to its use in children in the EU. Pediatr Drugs. 2015;17(2):167–74. doi:10.1007/s40272-015-0123-7.
   PubMed Web of Science ®Google Scholar
• Ma S-J, Li X, Xiong Y-Q, Yao A, Chen Q. Combination measles-mumps-rubella-varicella vaccine in healthy children. Medicine (Baltimore). 2015;94(44):e1721. doi:10.1097/MD.0000000000001721.
   PubMed Web of Science ®Google Scholar
• Shinefield H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, Brown ML, Eves KA, Klopfer SO, Schödel F, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24(8):665–69. doi:10.1097/01.inf.0000172902.25009.a1.
   PubMed Web of Science ®Google Scholar
• Nolan T, McIntyre P, Roberton D, Descamps D. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine. 2002;21(3–4):281–89. doi:10.1016/s0264-410x(02)00459-0.
   PubMed Web of Science ®Google Scholar
• Kuter BJ, Hoffman Brown ML, Hartzel J, Williams WR, EvesiKaren A, Black S, Shinefield H, Reisinger KS, Marchant CD, Sullivan BJ, et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad®). Hum Vaccin. 2006;2(5):205–14. doi:10.4161/hv.2.5.3246.
   PubMed Web of Science ®Google Scholar
• Knuf M, Habermehl P, Zepp F, Mannhardt W, Kuttnig M, Muttonen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J. 2006;25(1):12–18. doi:10.1097/01.inf.0000195626.35239.58.
   PubMed Web of Science ®Google Scholar
• Czajka H, Schuster V, Zepp F, Esposito S, Douha M, Willems P. A combined measles, mumps, rubella and varicella vaccine (Priorix-TetraTM): immunogenicity and safety profile. Vaccine. 2009;27(47):6504–11. doi:10.1016/j.vaccine.2009.07.076.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. Epidemiology and prevention of vaccine-preventable diseases. Meningococcal disease. [ accessed 2019 Sep 4]. https://www.cdc.gov/vaccines/pubs/pinkbook/chapters.html.
   Google Scholar
• Agenzia Italiana del Farmaco. Meningitec. Summary of product characteristics. [ accessed 2019 Sep 5]. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_003835_035438_FI.pdf&retry=0&sys=m0b1l3.
   Google Scholar
• Agenzia Italiana del Farmaco. Mencevax ACWY. Summary of product characteristics [Italian]. [ accessed 2019 Sep 4]. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000200_038504_RCP.pdf&retry=0&sys=m0b1l3.
   Google Scholar
• Agenzia Italiana del Farmaco. Menjugate. Summary of product characteristics [Italian]. [ accessed 2019 Sep 4]. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_007127_035436_RCP.pdf&retry=0&sys=m0b1l3.
   Google Scholar
• European Agency of Medicines. Menveo. Summary of product characteristics. [ accessed 2019 Sep 5]. https://www.ema.europa.eu/en/documents/product-information/menveo-epar-product-information_it.pdf.
   Google Scholar
• Agenzia Italiana per il Farmaco. NeisVac. Summary of product characteristics. [ accessed 2019 Sep 5]. https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_004025_035602_FI.pdf&retry=0&sys=m0b1l3.
   Google Scholar
• European Agency of Medicines. Nimenrix. Summary of product characteristics. [ accessed 2019 Sep 4]. https://www.ema.europa.eu/en/documents/product-information/nimenrix-epar-product-information_it.pdf.
   Google Scholar
• Richmond P, Borrow R, Miller E, Clark S, Sadler F, Fox A, Begg N, Morris R, Cartwright K. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis. 1999;179(6):1569–72. doi:10.1086/314753.
   PubMed Web of Science ®Google Scholar
• MacLennan JM, Shackley F, Heath PT, Deeks JJ, Flamank C, Herbert M, Griffiths H, Hatzmann E, Goilav C, Moxon ER. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants. JAMA. 2000;283(21):2795. doi:10.1001/jama.283.21.2795.
   PubMed Web of Science ®Google Scholar
• Levi M, Donzellini M, Varone O, Sala A, Bechini A, Boccalini S, Bonanni P. Surveillance of adverse events following immunization with meningococcal group C conjugate vaccine: tuscany, 2005-2012. J Prev Med Hyg. 2014;55(4):145–51. Accessed 2019 September 4. http://www.ncbi.nlm.nih.gov/pubmed/26137788.
   PubMedGoogle Scholar
• Lakshman R, Jones I, Walker D, McMurtrie K, Shaw L, Race G, Choo S, Danzing L, Oster P, Finn A. Safety of a new conjugate meningococcal C vaccine in infants. Arch Dis Child. 2001;85(5):391–97. doi:10.1136/adc.85.5.391.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis. 2010;29(3):259–67. doi:10.1007/s10096-009-0848-8.
   PubMed Web of Science ®Google Scholar
• Kurosky SK, Davis KL, Krishnarajah G. Effect of combination vaccines on completion and compliance of childhood vaccinations in the United States. Hum Vaccin Immunother. 2017;13(11):2494. doi:10.1080/21645515.2017.1362515.
   PubMed Web of Science ®Google Scholar
• Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, et al. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life. Pediatr Infect Dis J. 2008;27(8):724–30. doi:10.1097/INF.0b013e318170bb22.
   PubMed Web of Science ®Google Scholar
• Ministry of Health. Immunisation Handbook 2017. 2nd ed. [ accessed 2019 Sep 4]. https://www.health.govt.nz/publication/immunisation-handbook-2017.
   Google Scholar
• Government of Canada. Canadian immunization guide: part 1 - key immunization information. [ accessed 2019 Sep 4]. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-1-key-immunization-information/page-10-timing-vaccine-administration.html.
   Google Scholar
• GOV.UK. Contraindications and special considerations: the green book. Chapter 6.; 2017. [accessed. 2019 Sep 4]. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/655225/Greenbook_chapter_6.pdf.
   Google Scholar
• Gallo G, Mel R, Ros E, Filia A Guide to contraindications to vaccinations. Fifth Edition, 2018 [Guida alle Controindicazioni alle Vaccinazioni. Quinta Edizione, 2018]. [Italian]. [ accessed 2019 Sep 4]. http://www.salute.gov.it/imgs/C_17_pubblicazioni_2759_allegato.pdf.
   Google Scholar
• Italian Society of Hygiene, Preventive Medicine and Public Health - SItI, Italian Federation of Family Pediatricians-FIMP, Italian Federation of General Medicine-FIMMG, Italian Society for Pediatricians-SIP. Vaccination Calendar 2019 [Calendario Vaccinale per La Vita 2019] [Italian]. 2019. [accessed 2019 Sep 4]. http://www.igienistionline.it/docs/2019/21cvplv.pdf.
   Google Scholar